Further, Moderna said it … Pfizer reveals strong efficacy after six months with COVID-19 vaccine. So, as the trials were conducted differently at different times, efficacy rates cannot be directly compared among the vaccines. Just one dose of the Moderna and Pfizer two-shot coronavirus vaccines is seemingly nearly as good two. Moderna starts new variant-specific trial. Does it work against new variants? ; The vaccine appeared to have high effectiveness in clinical trials (efficacy) among people of diverse age, sex, race, and ethnicity … Researchers have found that the Moderna COVID-19 vaccine has proven effective in fighting off more contagious variants of the virus. Based on the evidence so far, the new variants of SARS-CoV-2, including the B.1.1.7 and the 501Y.V2, do not alter the effectiveness of the Moderna mRNA vaccine. Moderna reports its vaccine remains more than 90 percent effective after six months. Moderna's 6-month Review Of COVID-19 Vaccine Post Dose 2 Shows More Than 90% Efficacy ... increase neutralizing titers against SARS-CoV-2 variants of concern. In a study published Thursday in the New England Journal of Medicine, a pair of Canadian-based researchers suggested an amendment to the determined efficacy of the Pfizer vaccines after just one shot. Risks of the Moderna vaccine Researchers in the United States have conducted a pre-clinical study demonstrating the efficacy of two updated versions of the Moderna mRNA-1273 vaccine against variants of … Moderna is working on two variant-specific boosters, and said mice studies showed they elicited an increased immune response. The new variants or mutations of the COVID19 virus which were not part of the report include B.1.1.7, B.1.351 and P.1 variant strains that originated in the United Kingdom, South Africa, and Brazil, respectively. The Novavax COVID-19 vaccine candidate shows 89.3% efficacy in clinical trials, as well as 60–86% efficacy against emerging variants. In mid-March, CNBC reported the J&J shot demonstrated 64% efficacy in South Africa, where the more contagious and virulent B.1.351 variant is rapidly spreading. A pair of new studies found that the Moderna vaccine, which is one of three approved by the FDA for administration in the U.S., is effective against the California variant that has recently been rapidly spreading, with protection lasting for at least six months. The Moderna vaccine has been shown to have an efficacy of approximately 92 per cent in protecting against COVID-19, starting 14 days after the first dose. ... Moderna COVID-19 vaccine efficacy … Based on evidence from clinical trials, the Moderna vaccine was 94.1% effective at preventing laboratory-confirmed COVID-19 illness in people who received two doses who had no evidence of being previously infected. Moderna Inc. MRNA, +6.89% said late Tuesday that its COVID-19 vaccine continued to show "strong efficacy," including greater than 90% efficacy … The Pfizer and Moderna vaccines went through trials before the more contagious B.1.1.7, B.1.351 and P.1 variant strains that originated in the United … How Well the Vaccine Works. ... One shot is designed to protect against B.1.351, the variant first identified in South Africa.